MEPROBAMATE-containing
medicines in the European Union
are facing an uncertain future after
the European Medicines Agency
announced a blanket
suspension of the drugs’ marketing
approval.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 25 Jan 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.